No significant differences were found between the lenvatinib and TACE groups with respect to the etiology of liver disease, Eastern Cooperative Oncology Group performance status score, aspartate and alanine aminotransferase (AST and ALT) levels, gamma-glutamyl transferase level, hepatic reserve (Child–Pugh class or albumin–bilirubin score [24,25]) and α-fetoprotein and des-γ-carboxy prothrombin levels as tumor markers. This evidence concerns the gene GPT and liver disorder.